GlobeNewsWire
12 Jun 2026, 13:42 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is accused of using channel stuffing to report 20% revenue growth in 2025, while real growth was allegedly -3%. — Allegations of systemic revenue manipulation and artificial growth are severe red flags for valuation and corporate integrity.
-0.90A federal securities class action lawsuit has been filed against ADMA Biologics alleging false statements and lack of internal controls. — Legal action regarding securities fraud creates significant financial risk and potential for large settlements or penalties.
-0.60ADMA Biologics is alleged to have engaged in an undisclosed related party transaction. — Undisclosed related-party transactions suggest governance failures and a lack of transparency in financial reporting.
-0.50Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a federal securities class action lawsuit alleging channel stuffing, undisclosed related party transactions, and misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
29m ago
